POLICY WIRE FACT CHECK: Analyzing the Claims Regarding John Sununu’s $35 Million ‘Big Pharma’ Earnings
The Claim During the high-stakes U.S. Senate campaign race in New Hampshire, Democratic Representative Chris Pappas leveled a sharp financial accusation against his Republican opponent, former...
The Claim
During the high-stakes U.S. Senate campaign race in New Hampshire, Democratic Representative Chris Pappas leveled a sharp financial accusation against his Republican opponent, former Senator John E. Sununu. In a debate held on October 13, Pappas alleged that Sununu had ‘cashed in’ with the pharmaceutical industry following his tenure in office. Specifically, Pappas claimed that Sununu voted with ‘Big Pharma’ to keep drug prices high and subsequently earned ‘up to $35 million’ working for corporate special interests.
This claim circulated widely across political circles and social media, framing Sununu as a beneficiary of the pharmaceutical industry who prioritized corporate interests over public health. The specific $35 million figure served as the focal point of the narrative, suggesting a direct and massive correlation between Sununu’s legislative record and his personal wealth.
The Details & Investigation
An investigation into the $35 million figure requires a granular look at the financial disclosure forms filed by Sununu in 2025 and 2026. These forms require candidates to provide estimates of their net worth—including income, stocks, and real estate—within broad ranges. The records show that Sununu’s net worth is estimated to be between $7.9 million and $36.3 million. To arrive at the $35 million figure cited by Pappas, the Representative subtracted the high-end of Sununu’s 2009 assets ($855,000) from the high-end of his 2026 assets ($36.3 million). This methodology ignores the low-end of the range, which would result in a significantly lower growth figure—more than four times smaller than the claim presented.
Furthermore, the source of this wealth is subject to nuance. A significant portion of Sununu’s assets—approximately $5 million—stems from Boston Scientific, a medical technology company. While some critics may group medical tech under the umbrella of ‘Big Pharma,’ it is a distinct sector. The disclosure forms list his Boston Scientific holdings in a range of $5 million to $25 million. Pappas relied exclusively on the $25 million upper-end estimate to bolster his total $35 million claim, whereas regulatory filings suggest the actual value could be closer to the $5 million lower-end.
The investigation also examined Sununu’s professional activities post-Senate. Sununu joined the law firm Akin Gump Strauss Hauer & Feld in 2010 as an adjunct senior policy adviser. Records indicate he was not a registered lobbyist, and no lobbying disclosure filings exist for him personally regarding Congress or its staff. While the firm itself received $10.3 million from pharmaceutical clients between 2010 and 2019, the firm represents a vast array of other industries, including Amazon, Adobe, and various automotive groups. Attributing the firm’s total client revenue directly to Sununu’s personal earnings without context is a misleading interpretation of corporate employment.
In evaluating these facts, the claim qualifies as MISINFORMATION. While it is true that Sununu’s net worth increased since leaving office and that he worked with medical-related entities, the $35 million figure is derived from cherry-picking the highest possible estimates from broad disclosure ranges. By omitting the lower-end estimates and the distinction between medical technology and pharmaceutical manufacturing, the claim creates a deceptive impression of direct financial gain from lobbying.
The Verdict
The claim that John E. Sununu earned ‘up to $35 million’ from Big Pharma is MOSTLY FALSE. The figure relies entirely on the absolute highest estimates within broad financial disclosure ranges while ignoring the lower-end figures that would provide a much different reality. Additionally, the claim conflates the revenue of a law firm he worked for with his personal income and mischaracterizes medical technology assets as direct ‘Big Pharma’ payouts to maximize political impact.
*Counter-misinformation & disinformation investigation conducted by PolicyWire Editorial Desk (PW).
